Mandate

Vinge assisted Cantargia in entering into a R&D agreement with Panorama Research

August 24, 2017

Cantargia AB (“Cantargia”) of Lund, Sweden, and Panorama Research Inc. (“Panorama”), a California based specialist antibody developer, have entered into a collaboration agreement to jointly accelerate Cantargia's second program directed towards autoimmune and inflammatory diseases. 

Cantargia’s proprietary antibodies, against the molecular target IL1RAP, will be affinity matured and humanized using Panorama’s proprietary technology. In addition, Panorama will generate cell lines optimized for high level GMP production. Cantargia will be responsible for subsequent down-stream development. Under the terms of the agreement, Panorama will share risk in the project in exchange for a fraction of future incomes from third parties or future sales.
 
Kristoffer Franzkeit advised Cantargia.

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026